Clinical Trial Update: Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a proteasome inhibitor in relapsed or refractory B-cell lymphomas previously treated with chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma B-cell

Drugs mentioned

• PS-341 (bortezomib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma, B-Cell | Phase 2 | Status: COMPLETED